Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023
23 Juni 2023 - 2:00PM
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’
or the ‘Company’) a pharmaceutical company developing medicinal
cannabinoid pharmaceutical products and psychedelic therapies for
unmet medical needs, is pleased to announce that it will be
featured as a presenting company at the H.C. Wainwright 4th Annual
Neuropsychiatry Virtual Conference. The conference is being held
virtually on September 26, 2023.
Joel Latham, CEO of Incannex, will provide an
overview of the Company's business during the presentation.
If you are an institutional investor and would like to listen to
the Company’s presentation or request a 1x1 meeting, please click
on the following link
(https://hcwevents.com/neuropsychiatry-conference/) to register for
the conference.
Event: H.C. Wainwright 4th Annual
Neuropsychiatry Virtual Conference
Date: June 26, 2023
1x1 virtual meeting availability: June 26, 2023,
2:00-5:00pm (U.S. eastern time)
Webcast Link:
https://journey.ct.events/view/c9103120-be17-41c0-bfb4-3bcdfe658e51
Time/Location: Virtual to start on-demand
June 26th at 7:00am (U.S. eastern time)
About Incannex Healthcare
Limited
Incannex is a clinical stage pharmaceutical
development company that is developing unique medicinal cannabis
pharmaceutical products and psychedelic medicine therapies for the
treatment of obstructive sleep apnoea (OSA), traumatic brain injury
(TBI) and concussion, lung inflammation (ARDS, COPD, asthma,
bronchitis), rheumatoid arthritis, inflammatory bowel disease,
anxiety disorders, addiction disorders, and pain, among other
indications.
U.S. FDA approval and registration, subject to
ongoing clinical success, is being pursued for each drug and
therapy under development. Each indication under investigation
currently has no, or limited, existing registered pharmacotherapy
(drug) treatments available to the public and represent major
global economic opportunities to Incannex and its shareholders.
Incannex has a strong patent filing strategy in
place as it develops its products and therapies in conjunction with
its medical and scientific advisory board and partners. The Company
holds 19 granted patents and 30 pending patent applications.
Incannex is listed on the Australian Stock Exchange (ASX) with
stock code "IHL" and has American Depository Shares listed on
NASDAQ under code "IXHL".
Website:
www.incannex.com.au Investors:
investors@incannex.com.au
Forward-looking statements
This press release contains "forward-looking
statements" within the meaning of the "safe harbor" provisions of
the U.S. Private Securities Litigation Reform Act of 1995. These
forward-looking statements are made as of the date they were first
issued and were based on current expectations and estimates, as
well as the beliefs and assumptions of management. The
forward-looking statements included in this press release represent
Incannex's views as of the date of this press release. Incannex
anticipates that subsequent events and developments may cause its
views to change. Incannex undertakes no intention or obligation to
update or revise any forward-looking statements, whether as of a
result of new information, future events or otherwise. These
forward-looking statements should not be relied upon as
representing Incannex's views as of any date after the date of this
press release.
Contact Information
Incannex Healthcare LimitedMr
Joel LathamManaging Director and Chief Executive Officer+61 409 840
786joel@incannex.com.au
US IR ContactEdison GroupAlyssa
Factor +1-860-573-9637afactor@edisongroup.com
About H.C. Wainwright &
Co.
H.C. Wainwright is a full‐service investment
bank dedicated to providing corporate finance, strategic advisory
and related services to public and private companies across
multiple sectors and regions. H.C. Wainwright & Co.
also provides research and sales and trading services to
institutional investors. According to Sagient Research
Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent
in terms of aggregate CMPO (confidentially marketed public
offering), RD (registered direct offering) and PIPE (private
investment in public equity) executed cumulatively since 1998.
For more information visit H.C. Wainwright &
Co. on the web at www.hcwco.com.
Incannex Healthcare (NASDAQ:IXHL)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Incannex Healthcare (NASDAQ:IXHL)
Historical Stock Chart
Von Mai 2023 bis Mai 2024